| 1 | Clinical Impact of Microbiome Characteristics in Treatment-Naïve Extranodal NK/T-Cell Lymphoma Patients | 3.3 | 0 | Citations (PDF) |
| 2 | A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas | 6.8 | 12 | Citations (PDF) |
| 3 | Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia | 2.4 | 3 | Citations (PDF) |
| 4 | MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma | 3.4 | 0 | Citations (PDF) |
| 5 | Comprehensive clinico‐genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm | 2.7 | 0 | Citations (PDF) |
| 6 | Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphomaBlood, 2025, 146, 155-166 | 4.2 | 3 | Citations (PDF) |
| 7 | Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial | 22.5 | 34 | Citations (PDF) |
| 8 | Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up | 0.4 | 1 | Citations (PDF) |
| 9 | Peripheral T‐Cell Lymphoma: What's Next? | 2.1 | 0 | Citations (PDF) |
| 10 | Autologous stem cell transplantation in NK/T‐cell lymphoma: Prognostic impact of EBV‐DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party | 0.4 | 1 | Citations (PDF) |
| 11 | Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial | 1.0 | 19 | Citations (PDF) |
| 12 | Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies | 2.2 | 13 | Citations (PDF) |
| 13 | Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma | 2.0 | 4 | Citations (PDF) |
| 14 | Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma | 3.3 | 8 | Citations (PDF) |
| 15 | KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes | 6.8 | 4 | Citations (PDF) |
| 16 | Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial | 16.9 | 31 | Citations (PDF) |
| 17 | Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab | 1.5 | 4 | Citations (PDF) |
| 18 | Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study | 16.9 | 54 | Citations (PDF) |
| 19 | CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysisBlood, 2024, 144, 629-638 | 4.2 | 42 | Citations (PDF) |
| 20 | Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma | 1.5 | 3 | Citations (PDF) |
| 21 | Peripheral T-cell lymphoma: From biology to practice to the future | 9.6 | 7 | Citations (PDF) |
| 22 | Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma | 5.0 | 9 | Citations (PDF) |
| 23 | Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma | 2.7 | 3 | Citations (PDF) |
| 24 | Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial | 62.3 | 113 | Citations (PDF) |
| 25 | Mutational characteristics of extranodal NK/T-cell lymphoma analyzed in relation to clinical prognostic indices | 1.5 | 2 | Citations (PDF) |
| 26 | Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL) | 3.3 | 2 | Citations (PDF) |
| 27 | A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK | 3.3 | 6 | Citations (PDF) |
| 28 | Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas | 3.3 | 19 | Citations (PDF) |
| 29 | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | 3.3 | 5 | Citations (PDF) |
| 30 | A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma | 2.1 | 9 | Citations (PDF) |
| 31 | Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma | 2.0 | 8 | Citations (PDF) |
| 32 | Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404) | 3.3 | 7 | Citations (PDF) |
| 33 | Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialBlood, 2023, 141, 1971-1981 | 4.2 | 40 | Citations (PDF) |
| 34 | Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma | 2.6 | 4 | Citations (PDF) |
| 35 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | 0.7 | 5 | Citations (PDF) |
| 36 | In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas | 2.6 | 10 | Citations (PDF) |
| 37 | TET2 and LILRB1 mutations are frequent in Epstein–Barr virus‐positive diffuse large B‐cell lymphoma especially in elderly patients | 4.0 | 10 | Citations (PDF) |
| 38 | Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis | 3.3 | 12 | Citations (PDF) |
| 39 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 3.3 | 2 | Citations (PDF) |
| 40 | Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma | 1.5 | 2 | Citations (PDF) |
| 41 | Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis | 7.7 | 19 | Citations (PDF) |
| 42 | A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma | 2.6 | 7 | Citations (PDF) |
| 43 | The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network | 5.0 | 1 | Citations (PDF) |
| 44 | Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma | 2.7 | 0 | Citations (PDF) |
| 45 | Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ | 2.6 | 6 | Citations (PDF) |
| 46 | Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation | 2.6 | 3 | Citations (PDF) |
| 47 | Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma | 3.3 | 17 | Citations (PDF) |
| 48 | Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified | 1.4 | 9 | Citations (PDF) |
| 49 | PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells | 10.2 | 73 | Citations (PDF) |
| 50 | Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma | 2.6 | 9 | Citations (PDF) |
| 51 | Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis | 2.3 | 7 | Citations (PDF) |
| 52 | CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain | 5.0 | 8 | Citations (PDF) |
| 53 | Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma | 1.5 | 7 | Citations (PDF) |
| 54 | A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort | 6.5 | 13 | Citations (PDF) |
| 55 | Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma | 1.0 | 18 | Citations (PDF) |
| 56 | Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice | 16.9 | 33 | Citations (PDF) |
| 57 | EBV-associated NK and T-cell lymphoid neoplasms | 2.1 | 25 | Citations (PDF) |
| 58 | Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma | 3.8 | 9 | Citations (PDF) |
| 59 | Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management | 3.1 | 16 | Citations (PDF) |
| 60 | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis | 1.1 | 7 | Citations (PDF) |
| 61 | Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months | 2.6 | 10 | Citations (PDF) |
| 62 | Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study | 24.1 | 61 | Citations (PDF) |
| 63 | Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis | 11.6 | 6 | Citations (PDF) |
| 64 | Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping | 3.4 | 9 | Citations (PDF) |
| 65 | Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectBlood, 2021, 138, 213-220 | 4.2 | 110 | Citations (PDF) |
| 66 | Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 2.6 | 20 | Citations (PDF) |
| 67 | Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation | 3.4 | 7 | Citations (PDF) |
| 68 | Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications | 3.8 | 7 | Citations (PDF) |
| 69 | Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas | 7.8 | 30 | Citations (PDF) |
| 70 | EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma | 3.4 | 9 | Citations (PDF) |
| 71 | Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia | 3.4 | 44 | Citations (PDF) |
| 72 | Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma | 5.0 | 91 | Citations (PDF) |
| 73 | Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial | 9.6 | 137 | Citations (PDF) |
| 74 | Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels | 3.3 | 16 | Citations (PDF) |
| 75 | Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia | 1.5 | 7 | Citations (PDF) |
| 76 | Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34+ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation | 2.4 | 5 | Citations (PDF) |
| 77 | MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma | 2.3 | 4 | Citations (PDF) |
| 78 | Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy | 2.5 | 4 | Citations (PDF) |
| 79 | Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study | 1.5 | 23 | Citations (PDF) |
| 80 | Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing | 2.9 | 11 | Citations (PDF) |
| 81 | TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma | 1.0 | 0 | Citations (PDF) |
| 82 | Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis | 2.1 | 9 | Citations (PDF) |
| 83 | The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma | 2.9 | 13 | Citations (PDF) |
| 84 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study | 27.4 | 110 | Citations (PDF) |
| 85 | Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma | 2.5 | 6 | Citations (PDF) |
| 86 | Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study | 5.5 | 9 | Citations (PDF) |
| 87 | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | 3.3 | 6 | Citations (PDF) |
| 88 | Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas | 6.5 | 59 | Citations (PDF) |
| 89 | Impact of fear of cancer recurrence on survival among lymphoma patients | 3.0 | 27 | Citations (PDF) |
| 90 | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma | 1.5 | 3 | Citations (PDF) |
| 91 | Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations | 27.4 | 65 | Citations (PDF) |
| 92 | Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study | 6.5 | 130 | Citations (PDF) |
| 93 | A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score | 5.0 | 6 | Citations (PDF) |
| 94 | Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma | 3.8 | 20 | Citations (PDF) |
| 95 | Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 studyBlood, 2020, 136, 2754-2763 | 4.2 | 117 | Citations (PDF) |
| 96 | Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma | 7.7 | 67 | Citations (PDF) |
| 97 | First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial | 3.8 | 17 | Citations (PDF) |
| 98 | Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non‐Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma | 2.0 | 6 | Citations (PDF) |
| 99 | Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea | 8.1 | 18 | Citations (PDF) |
| 100 | Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group | 24.1 | 26 | Citations (PDF) |
| 101 | Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners | 2.1 | 12 | Citations (PDF) |
| 102 | Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma | 3.5 | 10 | Citations (PDF) |
| 103 | Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphomaBlood, 2020, 136, 2548-2556 | 4.2 | 27 | Citations (PDF) |
| 104 | Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project | 9.6 | 107 | Citations (PDF) |
| 105 | Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma | 2.9 | 36 | Citations (PDF) |
| 106 | A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group | 7.7 | 52 | Citations (PDF) |
| 107 | A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis | 1.5 | 12 | Citations (PDF) |
| 108 | Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas | 1.5 | 24 | Citations (PDF) |
| 109 | Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyBlood, 2020, 135, 735-742 | 4.2 | 105 | Citations (PDF) |
| 110 | Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk | 5.0 | 22 | Citations (PDF) |
| 111 | A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study | 1.5 | 39 | Citations (PDF) |
| 112 | Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified | 1.0 | 10 | Citations (PDF) |
| 113 | Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial | 3.3 | 40 | Citations (PDF) |
| 114 | Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study | 1.8 | 6 | Citations (PDF) |
| 115 | Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma | 1.4 | 16 | Citations (PDF) |
| 116 | The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores | 1.5 | 10 | Citations (PDF) |
| 117 | A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study | 3.4 | 22 | Citations (PDF) |
| 118 | Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma | 2.9 | 46 | Citations (PDF) |
| 119 | Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma | 2.9 | 26 | Citations (PDF) |
| 120 | Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 11.6 | 15 | Citations (PDF) |
| 121 | Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma | 1.5 | 70 | Citations (PDF) |
| 122 | A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial) | 1.4 | 4 | Citations (PDF) |
| 123 | Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes | 1.4 | 26 | Citations (PDF) |
| 124 | Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997–2016 | 1.2 | 8 | Citations (PDF) |
| 125 | Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis | 3.4 | 14 | Citations (PDF) |
| 126 | Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma | 1.0 | 6 | Citations (PDF) |
| 127 | Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapyBlood, 2019, 133, 137-146 | 4.2 | 115 | Citations (PDF) |
| 128 | Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma | 3.5 | 11 | Citations (PDF) |
| 129 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial | 62.3 | 667 | Citations (PDF) |
| 130 | Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression | 4.8 | 52 | Citations (PDF) |
| 131 | Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma | 3.3 | 17 | Citations (PDF) |
| 132 | Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas | 3.3 | 83 | Citations (PDF) |
| 133 | Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma | 3.3 | 9 | Citations (PDF) |
| 134 | CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL | 5.5 | 15 | Citations (PDF) |
| 135 | Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target | 13.7 | 136 | Citations (PDF) |
| 136 | Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis | 1.5 | 16 | Citations (PDF) |
| 137 | Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma | 1.5 | 16 | Citations (PDF) |
| 138 | Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study | 2.3 | 22 | Citations (PDF) |
| 139 | Early disease progression in patients with localized natural killer/T‐cell lymphoma treated with concurrent chemoradiotherapy | 3.9 | 20 | Citations (PDF) |
| 140 | Use of complementary and alternative medicine by lymphoma survivors in South Korea | 2.3 | 13 | Citations (PDF) |
| 141 | Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy | 2.5 | 7 | Citations (PDF) |
| 142 | Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay | 2.3 | 5 | Citations (PDF) |
| 143 | Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study | 2.9 | 15 | Citations (PDF) |
| 144 | Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma | 3.3 | 25 | Citations (PDF) |
| 145 | Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review | 24.1 | 67 | Citations (PDF) |
| 146 | Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T‐cell lymphoma | 3.9 | 17 | Citations (PDF) |
| 147 | Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement | 4.8 | 39 | Citations (PDF) |
| 148 | Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study | 1.5 | 6 | Citations (PDF) |
| 149 | The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms | 1.5 | 14 | Citations (PDF) |
| 150 | A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score | 5.5 | 10 | Citations (PDF) |
| 151 | Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation | 1.6 | 32 | Citations (PDF) |
| 152 | Validation of the Marginal Zone Lymphoma International Prognostic Index | 1.5 | 13 | Citations (PDF) |
| 153 | Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 StudyBlood, 2018, 132, 1618-1618 | 4.2 | 10 | Citations (PDF) |
| 154 | Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell LymphomaBlood, 2018, 132, 1595-1595 | 4.2 | 10 | Citations (PDF) |
| 155 | Validation of the Korean Version of the Quality of Life–Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors | 3.3 | 19 | Citations (PDF) |
| 156 | Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study | 3.3 | 26 | Citations (PDF) |
| 157 | Pitfalls and major issues in the histologic diagnosis of peripheral T‐cell lymphomas: results of the central review of 573 cases from the T‐Cell Project, an international, cooperative study | 2.1 | 20 | Citations (PDF) |
| 158 | Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma | 2.1 | 17 | Citations (PDF) |
| 159 | Atypical presentations of MERS-CoV infection in immunocompromised hosts | 1.4 | 38 | Citations (PDF) |
| 160 | Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B‐cell lymphoma | 2.1 | 26 | Citations (PDF) |
| 161 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial | 9.6 | 72 | Citations (PDF) |
| 162 | Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma | 2.7 | 23 | Citations (PDF) |
| 163 | Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy | 1.6 | 6 | Citations (PDF) |
| 164 | Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers | 5.5 | 8 | Citations (PDF) |
| 165 | Brentuximab vedotin: clinical updates and practical guidance | 1.8 | 48 | Citations (PDF) |
| 166 | Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma | 1.8 | 7 | Citations (PDF) |
| 167 | The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective | 1.8 | 2 | Citations (PDF) |
| 168 | IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma | 2.6 | 17 | Citations (PDF) |
| 169 | Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma | 16.9 | 376 | Citations (PDF) |
| 170 | Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial | 1.8 | 12 | Citations (PDF) |
| 171 | Recent advances in understanding and managing T-cell lymphoma | 0.5 | 4 | Citations (PDF) |
| 172 | Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma | 3.3 | 8 | Citations (PDF) |
| 173 | Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma | 2.2 | 6 | Citations (PDF) |
| 174 | Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update | 0.5 | 8 | Citations (PDF) |
| 175 | Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas | 1.8 | 11 | Citations (PDF) |
| 176 | Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients | 2.8 | 40 | Citations (PDF) |
| 177 | Clinical features and treatment outcome of Epstein–Barr virus-positive nodal T-cell lymphoma | 1.5 | 21 | Citations (PDF) |
| 178 | l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia | 24.1 | 35 | Citations (PDF) |
| 179 | Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability | 1.5 | 12 | Citations (PDF) |
| 180 | A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis | 27.4 | 357 | Citations (PDF) |
| 181 | Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study | 1.5 | 7 | Citations (PDF) |
| 182 | Clinical Features and Survival of Patients With Follicular Lymphoma in Korea | 1.0 | 4 | Citations (PDF) |
| 183 | CD79B limits response of diffuse large B cell lymphoma to ibrutinib | 1.4 | 39 | Citations (PDF) |
| 184 | Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)Blood, 2016, 128, 1807-1807 | 4.2 | 12 | Citations (PDF) |
| 185 | The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell LymphomaBlood, 2016, 128, 1820-1820 | 4.2 | 19 | Citations (PDF) |
| 186 | Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with PralatrexateBlood, 2016, 128, 4149-4149 | 4.2 | 5 | Citations (PDF) |
| 187 | Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation StudyBlood, 2016, 128, 4194-4194 | 4.2 | 1 | Citations (PDF) |
| 188 | Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)Blood, 2016, 128, 470-470 | 4.2 | 26 | Citations (PDF) |
| 189 | Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism | 3.3 | 35 | Citations (PDF) |
| 190 | Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell MalignanciesBlood, 2016, 128, 2921-2921 | 4.2 | 0 | Citations (PDF) |
| 191 | A Prognostic Index for Extranodal Natural Killer/T Cell Lymphoma after Non-Anthracycline-Based Treatment (PINK-B): Prognostic Index of Natural Killer Cell Lymphoma (PINK) Combined with Serum Beta-2 MicroglobulinBlood, 2016, 128, 1821-1821 | 4.2 | 3 | Citations (PDF) |
| 192 | A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) TrialBlood, 2016, 128, 1823-1823 | 4.2 | 0 | Citations (PDF) |
| 193 | Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)Blood, 2016, 128, 3466-3466 | 4.2 | 0 | Citations (PDF) |
| 194 | The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients | 24.1 | 36 | Citations (PDF) |
| 195 | Systemic Epstein-Barr virus-negative mature natural killer-cell lymphoma with cutaneous and visceral involvementApmis, 2015, 123, 990-992 | 2.5 | 4 | Citations (PDF) |
| 196 | Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T‐cell lymphoma, nasal type | 2.7 | 3 | Citations (PDF) |
| 197 | Integrated copy number and gene expression profiling analysis of epstein–barr virus‐positive diffuse large b‐cell lymphoma | 3.0 | 52 | Citations (PDF) |
| 198 | Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy | 3.9 | 23 | Citations (PDF) |
| 199 | Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly | 2.1 | 20 | Citations (PDF) |
| 200 | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study | 1.8 | 18 | Citations (PDF) |
| 201 | Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin | 1.8 | 68 | Citations (PDF) |
| 202 | Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea | 1.5 | 11 | Citations (PDF) |
| 203 | Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B‐cell lymphoma | 3.9 | 26 | Citations (PDF) |
| 204 | Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis | 9.6 | 99 | Citations (PDF) |
| 205 | Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome | 1.5 | 41 | Citations (PDF) |
| 206 | Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial | 9.6 | 58 | Citations (PDF) |
| 207 | Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | 1.5 | 31 | Citations (PDF) |
| 208 | Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma | 1.6 | 85 | Citations (PDF) |
| 209 | PKD1 is critical for Epstein–Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab | 1.4 | 4 | Citations (PDF) |
| 210 | Weekly rituximab consolidation following four cycles of R‐CHOP induction chemotherapy in very elderly patients with diffuse large B‐cell lymphoma: Consortium for improving survival of lymphoma study (CISL) | 1.8 | 16 | Citations (PDF) |
| 211 | Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial | 1.5 | 45 | Citations (PDF) |
| 212 | Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study | 1.5 | 3 | Citations (PDF) |
| 213 | Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement | 1.5 | 6 | Citations (PDF) |
| 214 | KIR alloreactivity based on the receptor–ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study | 1.0 | 11 | Citations (PDF) |
| 215 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose | 2.5 | 30 | Citations (PDF) |
| 216 | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma | 1.4 | 34 | Citations (PDF) |
| 217 | Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis | 1.5 | 38 | Citations (PDF) |
| 218 | An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)Blood, 2015, 126, 1493-1493 | 4.2 | 6 | Citations (PDF) |
| 219 | Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 StudyBlood, 2015, 126, 256-256 | 4.2 | 2 | Citations (PDF) |
| 220 | Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)Blood, 2015, 126, 5111-5111 | 4.2 | 5 | Citations (PDF) |
| 221 | Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis | 3.3 | 16 | Citations (PDF) |
| 222 | Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis | 3.3 | 12 | Citations (PDF) |
| 223 | Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal TypeBlood, 2015, 126, 3942-3942 | 4.2 | 0 | Citations (PDF) |
| 224 | Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant RecipientsBlood, 2015, 126, 1904-1904 | 4.2 | 1 | Citations (PDF) |
| 225 | Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic PhaseBlood, 2015, 126, 5160-5160 | 4.2 | 0 | Citations (PDF) |
| 226 | Prevalence and Prognostic Impact of CD30 and EBV Co-Expression in Korean Patients with EBV-Positive DLBCL of the ElderlyBlood, 2015, 126, 5021-5021 | 4.2 | 0 | Citations (PDF) |
| 227 | Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer CellsBlood, 2015, 126, 700-700 | 4.2 | 0 | Citations (PDF) |
| 228 | Tuberculosis in Hematopoietic Stem Cell Transplant Recipients in Korea | 1.5 | 21 | Citations (PDF) |
| 229 | Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma | 1.8 | 19 | Citations (PDF) |
| 230 | A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma | 2.7 | 113 | Citations (PDF) |
| 231 | Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP | 2.4 | 56 | Citations (PDF) |
| 232 | Indolent CD56-Positive Clonal T-Cell Lymphoproliferative Disease of the Stomach Mimicking Lymphomatoid Gastropathy | 0.7 | 3 | Citations (PDF) |
| 233 | Dexamethasone, methotrexate, ifosfamide,l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma | 1.4 | 3 | Citations (PDF) |
| 234 | A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma | 25.2 | 366 | Citations (PDF) |
| 235 | Health-related quality of life in Korean lymphoma survivors compared with the general population | 1.5 | 17 | Citations (PDF) |
| 236 | Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study | 1.5 | 124 | Citations (PDF) |
| 237 | CD79B and MYD88 mutations in diffuse large B-cell lymphoma | 2.3 | 47 | Citations (PDF) |
| 238 | Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients | 1.5 | 63 | Citations (PDF) |
| 239 | An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular LymphomaBlood, 2014, 124, 1718-1718 | 4.2 | 10 | Citations (PDF) |
| 240 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell LymphomaBlood, 2014, 124, 4443-4443 | 4.2 | 5 | Citations (PDF) |
| 241 | A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)Blood, 2014, 124, 503-503 | 4.2 | 12 | Citations (PDF) |
| 242 | A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Blood, 2014, 124, 5465-5465 | 4.2 | 2 | Citations (PDF) |
| 243 | Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell LymphomaBlood, 2014, 124, 4421-4421 | 4.2 | 0 | Citations (PDF) |
| 244 | Clinical Relevance of CD45+/CD19- Stem-like Tumor Cells in Patients with Mantle Cell Lymphoma: A Single Center ExperienceBlood, 2014, 124, 1622-1622 | 4.2 | 0 | Citations (PDF) |
| 245 | Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation | 1.5 | 36 | Citations (PDF) |
| 246 | Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior | 1.5 | 21 | Citations (PDF) |
| 247 | Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia | 1.5 | 21 | Citations (PDF) |
| 248 | Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma | 2.1 | 33 | Citations (PDF) |
| 249 | A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas | 2.5 | 9 | Citations (PDF) |
| 250 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group | 4.9 | 110 | Citations (PDF) |
| 251 | Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group | 24.1 | 77 | Citations (PDF) |
| 252 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) | 10.0 | 203 | Citations (PDF) |
| 253 | EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood | 0.7 | 48 | Citations (PDF) |
| 254 | Primary Cardiac Lymphoma Mimicking Infiltrative Cardiomyopathy | 7.4 | 11 | Citations (PDF) |
| 255 | Epstein–Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma | 1.4 | 42 | Citations (PDF) |
| 256 | Plerixafor use for peripheral blood stem cell mobilization in Korea | 1.8 | 5 | Citations (PDF) |
| 257 | Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry | 1.8 | 6 | Citations (PDF) |
| 258 | Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party | 1.8 | 14 | Citations (PDF) |
| 259 | Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay | 1.5 | 22 | Citations (PDF) |
| 260 | DCEP for relapsed or refractory multiple myeloma after therapy with novel agents | 1.5 | 33 | Citations (PDF) |
| 261 | Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal TypeBlood, 2013, 122, 3037-3037 | 4.2 | 2 | Citations (PDF) |
| 262 | Clinical Characteristics and Outcomes Of Waldeyer’s Ring Lymphoma: Nation-Wide Study In KoreaBlood, 2013, 122, 4332-4332 | 4.2 | 1 | Citations (PDF) |
| 263 | Weekly Four Times Rituximab Consolidation Following Reduced Cycles Of R-CHOP Induction Chemotherapy In Extremely Elderly Patients With Diffuse Large B Cell LymphomaBlood, 2013, 122, 3031-3031 | 4.2 | 0 | Citations (PDF) |
| 264 | Neutropenic and Non-Neutropenic Fever In Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-CHOP ChemotherapyBlood, 2013, 122, 5103-5103 | 4.2 | 0 | Citations (PDF) |
| 265 | Epstein–Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1 | 1.4 | 59 | Citations (PDF) |
| 266 | Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma | 1.4 | 12 | Citations (PDF) |
| 267 | 11C-Methionine PET/CT and MRI of Primary Central Nervous System Diffuse Large B-cell Lymphoma Before and After High-Dose Methotrexate | 2.4 | 20 | Citations (PDF) |
| 268 | Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group | 1.4 | 37 | Citations (PDF) |
| 269 | Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value? | 1.4 | 13 | Citations (PDF) |
| 270 | SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study GroupBlood, 2012, 120, 2973-2980 | 4.2 | 400 | Citations (PDF) |
| 271 | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 24.1 | 92 | Citations (PDF) |
| 272 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial | 4.9 | 109 | Citations (PDF) |
| 273 | Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population | 2.3 | 57 | Citations (PDF) |
| 274 | Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells | 0.7 | 14 | Citations (PDF) |
| 275 | Waldeyer’s ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL) | 1.5 | 5 | Citations (PDF) |
| 276 | Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study | 1.5 | 22 | Citations (PDF) |
| 277 | A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas | 0.9 | 11 | Citations (PDF) |
| 278 | Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype? | 0.9 | 9 | Citations (PDF) |
| 279 | Matched‐pair analysis comparing the outcomes of primary breast and nodal diffuse large B‐cell lymphoma in patients treated with rituximab plus chemotherapy | 4.3 | 48 | Citations (PDF) |
| 280 | Type II enteropathy‐associated T‐cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group | 6.5 | 162 | Citations (PDF) |
| 281 | The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma | 6.5 | 43 | Citations (PDF) |
| 282 | Aggressive natural killer cell leukemia: Therapeutic potential of l‐asparaginase and allogeneic hematopoietic stem cell transplantation | 3.9 | 78 | Citations (PDF) |
| 283 | The International Prognostic Index Is a Better Predictor of Thrombotic Complications Than the Khorana Score for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Results of a Single Center Prospective Cohort StudyBlood, 2012, 120, 5095-5095 | 4.2 | 0 | Citations (PDF) |
| 284 | Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement.Blood, 2012, 120, 2683-2683 | 4.2 | 0 | Citations (PDF) |
| 285 | Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained ResponseBlood, 2012, 120, 3669-3669 | 4.2 | 0 | Citations (PDF) |
| 286 | The Impact of Activated Akt Expression On Clinical Outcome in Diffuse Large B-Cell Lymphoma: A Clinicopathological Study of 99 Cases.Blood, 2012, 120, 2676-2676 | 4.2 | 1 | Citations (PDF) |
| 287 | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) | 2.9 | 122 | Citations (PDF) |
| 288 | Extranodal NK/T-cell lymphoma presented as panniculitis of breast in a male patient: A case report | 0.1 | 0 | Citations (PDF) |
| 289 | Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus | 1.6 | 33 | Citations (PDF) |
| 290 | Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy aloneBlood, 2011, 117, 1958-1965 | 4.2 | 131 | Citations (PDF) |
| 291 | Genomic profiling combined with gene expression profiling in primary central nervous system lymphomaBlood, 2011, 117, 1291-1300 | 4.2 | 100 | Citations (PDF) |
| 292 | Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis | 2.9 | 13 | Citations (PDF) |
| 293 | Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes | 1.5 | 56 | Citations (PDF) |
| 294 | Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation | 1.5 | 7 | Citations (PDF) |
| 295 | Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation | 1.5 | 23 | Citations (PDF) |
| 296 | Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy | 24.1 | 37 | Citations (PDF) |
| 297 | Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy | 1.4 | 3 | Citations (PDF) |
| 298 | Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL) | 1.5 | 12 | Citations (PDF) |
| 299 | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | 1.5 | 58 | Citations (PDF) |
| 300 | Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomasBlood, 2011, 118, 1642-1642 | 4.2 | 2 | Citations (PDF) |
| 301 | Primary Gastrointestinal Follicular Lymphoma: Single-Center 12 Year Experiences | 0.7 | 1 | Citations (PDF) |
| 302 | Stage I or II Marginal Zone B-Cell Lymphoma; Multicenter Retrospective Analysis of 217 CasesBlood, 2011, 118, 5219-5219 | 4.2 | 0 | Citations (PDF) |
| 303 | Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including Camphylobacter JejuniBlood, 2011, 118, 5224-5224 | 4.2 | 0 | Citations (PDF) |
| 304 | Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in KoreaBlood, 2011, 118, 2021-2021 | 4.2 | 0 | Citations (PDF) |
| 305 | Acute Myeloid Leukemia with Myelodysplasia-Related Changes (MRC) Did Not Show Inferior Outcomes Compared to Those without MRC,Blood, 2011, 118, 3563-3563 | 4.2 | 0 | Citations (PDF) |
| 306 | Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort StudyBlood, 2011, 118, 1595-1595 | 4.2 | 0 | Citations (PDF) |
| 307 | 18 F‐FDG uptake and its clinical relevance in primary gastric lymphoma | 2.1 | 43 | Citations (PDF) |
| 308 | Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea | 1.5 | 10 | Citations (PDF) |
| 309 | Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients | 1.5 | 23 | Citations (PDF) |
| 310 | A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation | 1.5 | 11 | Citations (PDF) |
| 311 | Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study | 1.5 | 14 | Citations (PDF) |
| 312 | Treatment of localized extranodal NK/T cell lymphoma, nasal type | 1.5 | 50 | Citations (PDF) |
| 313 | Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study | 2.9 | 76 | Citations (PDF) |
| 314 | Epstein–Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1 | 3.5 | 18 | Citations (PDF) |
| 315 | Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report | 0.7 | 31 | Citations (PDF) |
| 316 | Involved-Lesion Radiation Therapy After Chemotherapy in Limited-Stage Head-and-Neck Diffuse Large B Cell Lymphoma | 1.5 | 23 | Citations (PDF) |
| 317 | Stage IV marginal zone B‐cell lymphoma – prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study | 3.9 | 9 | Citations (PDF) |
| 318 | Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system | 2.0 | 2 | Citations (PDF) |
| 319 | Hodgkin's Lymphoma Arising in a Patient With Hypersensitivity to Mosquito Bites: A Case Report | 16.9 | 10 | Citations (PDF) |
| 320 | Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma | 1.0 | 94 | Citations (PDF) |
| 321 | Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy | 1.8 | 17 | Citations (PDF) |
| 322 | Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma | 1.5 | 27 | Citations (PDF) |
| 323 | Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity | 2.5 | 18 | Citations (PDF) |
| 324 | Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study.Blood, 2010, 116, 1790-1790 | 4.2 | 2 | Citations (PDF) |
| 325 | The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study.Blood, 2010, 116, 1791-1791 | 4.2 | 2 | Citations (PDF) |
| 326 | Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II StudyBlood, 2010, 116, 2873-2873 | 4.2 | 2 | Citations (PDF) |
| 327 | Side Population Cells of Human B-Cell Non-Hodgkin Lymphoma Cell Lines May Contain Lymphoma-Stem Cells Responsible for Lymphoma InitiationBlood, 2010, 116, 3105-3105 | 4.2 | 0 | Citations (PDF) |
| 328 | Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients.Blood, 2010, 116, 4494-4494 | 4.2 | 0 | Citations (PDF) |
| 329 | Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20+ Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.Blood, 2010, 116, 1786-1786 | 4.2 | 0 | Citations (PDF) |
| 330 | Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy In Stage I/II Extranodal NK/T-Cell Lymphoma of Nasal Cavity/NasopharynxBlood, 2010, 116, 1765-1765 | 4.2 | 0 | Citations (PDF) |
| 331 | Aggressive NK Cell Leukemia (ANKL): Experience with 34 Patients and Therapeutic Potentials of L-Asparaginase and Allogeneic Hematopoietic Cell Transplantation - A Japan-Korea Multicenter Study for ANKL (ANKL07) -Blood, 2010, 116, 3091-3091 | 4.2 | 0 | Citations (PDF) |
| 332 | Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?Blood, 2010, 116, 5084-5084 | 4.2 | 0 | Citations (PDF) |
| 333 | Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow TransplantationBlood, 2010, 116, 3536-3536 | 4.2 | 1 | Citations (PDF) |
| 334 | A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma | 1.4 | 7 | Citations (PDF) |
| 335 | Depletion of l‐ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes | 1.8 | 20 | Citations (PDF) |
| 336 | Relapsed or refractory nongastric marginal zone B‐cell lymphoma: Multicenter retrospective analysis of 92 cases | 6.5 | 11 | Citations (PDF) |
| 337 | Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea | 1.5 | 25 | Citations (PDF) |
| 338 | Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas | 1.4 | 16 | Citations (PDF) |
| 339 | Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome | 1.6 | 50 | Citations (PDF) |
| 340 | Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea | 1.4 | 22 | Citations (PDF) |
| 341 | Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma | 1.4 | 65 | Citations (PDF) |
| 342 | Prognostic significance of anatomic subsites: Results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma | 2.0 | 52 | Citations (PDF) |
| 343 | Clinical Characteristics of Primary Thyroid Lymphoma in Koreans | 1.6 | 71 | Citations (PDF) |
| 344 | Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study | 1.5 | 57 | Citations (PDF) |
| 345 | Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial | 2.5 | 10 | Citations (PDF) |
| 346 | Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma | 2.5 | 15 | Citations (PDF) |
| 347 | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial | 2.5 | 12 | Citations (PDF) |
| 348 | Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma.Blood, 2009, 114, 2688-2688 | 4.2 | 26 | Citations (PDF) |
| 349 | Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.Blood, 2009, 114, 5009-5009 | 4.2 | 0 | Citations (PDF) |
| 350 | Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.Blood, 2009, 114, 4999-4999 | 4.2 | 0 | Citations (PDF) |
| 351 | Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.Blood, 2009, 114, 5017-5017 | 4.2 | 0 | Citations (PDF) |
| 352 | Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.Blood, 2009, 114, 3751-3751 | 4.2 | 1 | Citations (PDF) |
| 353 | Excessive Toxicity of Once Daily Intravenous Busulfan, Melphalan, and Thiotepa Followed by Autologous Stem Cell Transplantation On Patients with Non-Hodgkin's Lymphoma.Blood, 2009, 114, 4361-4361 | 4.2 | 9 | Citations (PDF) |
| 354 | Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).Blood, 2009, 114, 4992-4992 | 4.2 | 0 | Citations (PDF) |
| 355 | Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea.Blood, 2009, 114, 5024-5024 | 4.2 | 7 | Citations (PDF) |
| 356 | Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma | 2.3 | 7 | Citations (PDF) |
| 357 | Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients | 2.9 | 18 | Citations (PDF) |
| 358 | TNFAIP3 is the target gene of chromosome band 6q23.3‐q24.1 loss in ocular adnexal marginal zone B cell lymphoma | 3.0 | 87 | Citations (PDF) |
| 359 | Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia | 3.9 | 201 | Citations (PDF) |
| 360 | Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification‐Based Prognostic Scoring System (WPSS) and comparison with IPSS | 1.8 | 46 | Citations (PDF) |
| 361 | Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study | 1.6 | 138 | Citations (PDF) |
| 362 | SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death | 1.4 | 18 | Citations (PDF) |
| 363 | Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma | 1.4 | 22 | Citations (PDF) |
| 364 | Relapsed Intravascular Large B-cell Lymphoma in the Lungs | 0.9 | 0 | Citations (PDF) |
| 365 | Rituximab-induced acute thrombocytopenia: a case report and review of the literature | 2.3 | 32 | Citations (PDF) |
| 366 | Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract | 2.3 | 32 | Citations (PDF) |
| 367 | Clinical features and prognostic factors of patients with “peripheral T cell lymphoma, unspecified” | 1.5 | 32 | Citations (PDF) |
| 368 | Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome | 1.5 | 31 | Citations (PDF) |
| 369 | A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma | 2.1 | 10 | Citations (PDF) |
| 370 | Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?Blood, 2008, 112, 4219-4219 | 4.2 | 0 | Citations (PDF) |
| 371 | Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic LymphomaBlood, 2008, 112, 3601-3601 | 4.2 | 20 | Citations (PDF) |
| 372 | Alemtuzumab and DHAP (A-DHAP) Is An Effective Salvage Therapy for Peripheral T-Cell Lymphoma, Unspecified: Interim Results of a Phase II Prospective Multicenter StudyBlood, 2008, 112, 5002-5002 | 4.2 | 0 | Citations (PDF) |
| 373 | Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?Blood, 2008, 112, 2833-2833 | 4.2 | 0 | Citations (PDF) |
| 374 | Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation | 1.6 | 47 | Citations (PDF) |
| 375 | Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study | 8.6 | 19 | Citations (PDF) |
| 376 | Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1 | 2.7 | 22 | Citations (PDF) |
| 377 | Paclitaxel with Cisplatin as Salvage Treatment for Patients with Previously Treated Advanced Transitional Cell Carcinoma of the Urothelial Tract | 7.0 | 32 | Citations (PDF) |
| 378 | The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphomaBlood, 2007, 110, 972-978 | 4.2 | 298 | Citations (PDF) |
| 379 | Postremission therapy for acute myeloid leukemia in the first remission | 1.4 | 7 | Citations (PDF) |
| 380 | Quantifing the Circulating Epstein-Barr Virus (EBV) DNA to Monitor a Case of Aggressive Natural Killer Cell Leukemia | 0.9 | 0 | Citations (PDF) |
| 381 | Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases | 6.5 | 42 | Citations (PDF) |
| 382 | Consideration of aggressive therapeutic strategies for primary testicular lymphoma | 6.5 | 41 | Citations (PDF) |
| 383 | Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: Comparison with pulmonary and nodal marginal zone B cell lymphoma | 3.0 | 54 | Citations (PDF) |
| 384 | Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma | 0.7 | 42 | Citations (PDF) |
| 385 | What is stage II in high-grade primary gastric lymphoma? | 0.7 | 2 | Citations (PDF) |
| 386 | Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma | 2.7 | 68 | Citations (PDF) |
| 387 | Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease | 1.8 | 15 | Citations (PDF) |
| 388 | Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome | 1.5 | 150 | Citations (PDF) |
| 389 | Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP | 2.1 | 6 | Citations (PDF) |
| 390 | The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea.Blood, 2007, 110, 1892-1892 | 4.2 | 2 | Citations (PDF) |
| 391 | Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.Blood, 2007, 110, 1914-1914 | 4.2 | 1 | Citations (PDF) |
| 392 | A Phase I Trial of Bortezomib Plus CHOP Every 2 Weeks in Patients with Advanced Stage Diffuse Large B-Cell Lymphomas.Blood, 2007, 110, 4446-4446 | 4.2 | 2 | Citations (PDF) |
| 393 | Frequent CD7 Antigen Loss in Aggressive Natural Killer-Cell Leukemia Can Be a Useful Diagnostic Marker.Blood, 2007, 110, 2400-2400 | 4.2 | 0 | Citations (PDF) |
| 394 | A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin’s Lymphoma.Blood, 2007, 110, 3446-3446 | 4.2 | 0 | Citations (PDF) |
| 395 | Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.Blood, 2007, 110, 1361-1361 | 4.2 | 0 | Citations (PDF) |
| 396 | High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 casesin the Korean population | 1.4 | 14 | Citations (PDF) |
| 397 | Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study | 16.9 | 593 | Citations (PDF) |
| 398 | Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome | 0.7 | 12 | Citations (PDF) |
| 399 | Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia | 1.5 | 21 | Citations (PDF) |
| 400 | Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma | 1.5 | 43 | Citations (PDF) |
| 401 | CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation | 1.4 | 19 | Citations (PDF) |
| 402 | Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission | 1.5 | 6 | Citations (PDF) |
| 403 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study | 2.1 | 41 | Citations (PDF) |
| 404 | Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer | 1.6 | 6 | Citations (PDF) |
| 405 | Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission | 1.6 | 35 | Citations (PDF) |
| 406 | Curcumin inhibits interferon-α induced NF-κB and COX-2 in human A549 non-small cell lung cancer cells | 2.1 | 61 | Citations (PDF) |
| 407 | Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy | 4.9 | 153 | Citations (PDF) |
| 408 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer | 2.1 | 37 | Citations (PDF) |
| 409 | Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment | 1.4 | 52 | Citations (PDF) |
| 410 | Primary Pulmonary Non-Hodgkin's Lymphoma | 1.6 | 110 | Citations (PDF) |
| 411 | Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma | 2.1 | 85 | Citations (PDF) |
| 412 | Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen | 1.3 | 41 | Citations (PDF) |
| 413 | Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria | 1.6 | 201 | Citations (PDF) |
| 414 | Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer | 1.6 | 5 | Citations (PDF) |
| 415 | Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer | 1.6 | 3 | Citations (PDF) |
| 416 | Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial | 1.6 | 106 | Citations (PDF) |
| 417 | Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer | 1.3 | 18 | Citations (PDF) |
| 418 | Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies | 6.5 | 67 | Citations (PDF) |
| 419 | Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma | 2.5 | 126 | Citations (PDF) |
| 420 | Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study | 3.2 | 127 | Citations (PDF) |
| 421 | A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer | 3.3 | 0 | Citations (PDF) |
| 422 | Locoregional Response and Increased Natural Killer Activity after Intratumoral Injection of HLA-B7/β2-Microglobulin Gene in Patients with Cancer | 3.2 | 12 | Citations (PDF) |
| 423 | Production of IL-12 from gene modified human dermal fibroblasts: A preclinical study for IL-12 cancer gene therapy | 11.3 | 11 | Citations (PDF) |
| 424 | Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis | 1.1 | 0 | Citations (PDF) |
| 425 | Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma | 5.0 | 2 | Citations (PDF) |
| 426 | Clinical outcomes of tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma: insights from a single-center study | 1.5 | 0 | Citations (PDF) |
| 427 | Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group | 2.1 | 0 | Citations (PDF) |
| 428 | Aggressive natural killer cell leukemia therapy in the L-asparaginase era: why are we failing? | 1.8 | 0 | Citations (PDF) |
| 429 | Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group | 2.1 | 0 | Citations (PDF) |
| 430 | Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study | 2.9 | 0 | Citations (PDF) |
